French Language Validation of the 5-minutes Montreal Cognitive Assessment (MoCA)
NCT ID: NCT03232697
Last Updated: 2020-09-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
236 participants
INTERVENTIONAL
2017-07-12
2019-08-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of a Digital Self-Administered Cognitive Screening Tool: MoCA-XpressO
NCT05879562
Application and Revision of Montreal Cognitive Assessment in Chinese Retirees
NCT02483754
Post-stroke Cognitive Impairment and Dementia
NCT01339195
Social-cognitive Functioning: Validation of a New Neuropsychological Test
NCT05558709
Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen
NCT03811184
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main aim of the study is to validate the french translation of the short version of the MOCA as compared the the full french version of the test.
To validate the short version, several groups of subjects will be included : healthy subjects, Alzheimer disease patients, Parkinson or Huntington diseases patients as well as diabetic patients.
The inclusion of both healthy subjects and patients with different types of cognitive impairments will allow to validate the short version of the test.
All subjects and patients will first be submitted to the full version of the MOCA during a face to face procedure. Thirty to forty days later, they will be submitted to the short version of the test through a phone call performed by an independent rater.
Subgroups of healthy subjects and patients will also be used to determine the test-retest and inter-rater reliability of the short version of the MOCA.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy subjects
Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
Full version of the Montreal Cognitive Assessment
Patients or subjects will be submitted to the full version of the MOCA
5 minutes version of the Montreal Cognitive Assessment
The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
Alzheimer patients
Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
Full version of the Montreal Cognitive Assessment
Patients or subjects will be submitted to the full version of the MOCA
5 minutes version of the Montreal Cognitive Assessment
The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
Parkinson and Huntington patients
Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
Full version of the Montreal Cognitive Assessment
Patients or subjects will be submitted to the full version of the MOCA
5 minutes version of the Montreal Cognitive Assessment
The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
Diabetic patients
Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
Full version of the Montreal Cognitive Assessment
Patients or subjects will be submitted to the full version of the MOCA
5 minutes version of the Montreal Cognitive Assessment
The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Full version of the Montreal Cognitive Assessment
Patients or subjects will be submitted to the full version of the MOCA
5 minutes version of the Montreal Cognitive Assessment
The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Volunteers, BMI \<26
* free from neurological, psychiatric, metabolic or cardiac pathologies;
* Absence of active metabolic or cardiac diseases, unstabilized under treatment
* Pregnant test negative
Patients
* Patients suffering from pathologies that may be accompanied by cognitive decline or dementia (Alzheimer's disease, Parkinson's and Huntington's disease, diabetes) that meet the usual diagnostic criteria for these diseases;
* Patients should not start treatment of a new therapeutic class under test
Exclusion Criteria
* Illiterate subjects
* Presence of uncorrected visual or auditory disturbances
* "Alcohol use disorder" observed at the Mini International Neuropsychiatric Inventory (MINI);
* "Substance use disorder" observed at the MINI;
* Participation in a therapeutic trial or in an exclusion period from a previous clinical trial;
* Patient whose physical or mental condition does not allow them to pass the study tests;
* Persons under guardianship or under trusteeship;
* Recent cognitive assessment (less than 6 months) by the classic MoCA
40 Years
89 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Lille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dominique Deplanque, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Lille
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital
Lille, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A00131-52
Identifier Type: OTHER
Identifier Source: secondary_id
2016_47
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.